Experimental HCV Drugs
Experimental HCV Drugs
CROI 2014: Daclatasvir + Simeprevir Effective Against Hepatitis C Genotype 1b
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 11 March 2014 00:00
- Written by Liz Highleyman
An all-oral regimen of daclatasvir plus simeprevir, without interferon or ribavirin, led to sustained response in 85% to 95% of patients with hepatitis C genotype 1b, but this combination did not work well against genotype 1a, researchers reported last week at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) in Boston.
Coverage of the 2014 Conference on Retroviruses and Opportunistic Infections
- Details
- Category: HIV Treatment
- Published on Sunday, 09 March 2014 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014), March 3-6, 2014, in Boston.
Conference highlights include new treatments for hepatitis C, HIV experimental therapies and treatment strategies, HIV cure research, HIV-related conditions, treatment as prevention and PrEP, and HIV/HCV coinfection.
Selected presentations and slide webcasts
3/9/14
CROI 2014: Simeprevir Cures Almost 80% of First-time HIV/HCV Coinfected Patients
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 04 March 2014 16:11
- Written by Keith Alcorn
The next-generation hepatitis C protease inhibitor simeprevir (Olysio) cured nearly 80% of previously untreated people with hepatitis C and HIV coinfection when used in combination with pegylated interferon and ribavirin, Douglas Dieterich of Mt. Sinai Medical Center reported on Tuesday at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) in Boston.
Coverage of the 2014 Conference on Retroviruses and Opportunistic Infections
- Details
- Category: HIV Treatment
- Published on Sunday, 09 March 2014 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of the 21st Conference on Retroviruses and Opportunistic infections (CROI 2014), March 3-6, 2014, in Boston.
Conference highlights include new treatments for hepatitis C, HIV experimental therapies and treatment strategies, HIV cure research, HIV-related conditions, treatment as prevention and PrEP, and HIV/HCV coinfection.
Full HIVandHepatitis.com coverage by topic
Selected presentations and slide webcasts
3/9/14
CROI 2014: AbbVie 3D Combination Cures 99% of Genotype 1b Hepatitis C
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 04 March 2014 16:11
- Written by Keith Alcorn
A 12-week triple combination of direct-acting antivirals developed by AbbVie cured at least 99% of previously untreated people with genotype 1 hepatitis C infection, Rajendar Reddy of the University of Pennsylvania Hospital told the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) in Boston on Tuesday. This is expected to be the first approved interferon- and ribavirin-free combination for genotype 1b, available by the end of 2014.
Web Design and Development by